Predict Parkinson or dementia risk
- Trial ID
- NCT06629207
- Official Title
- Artificial Intelligence on Molecular Imaging to Predict the Risks of Parkinson's Disease for Patients With Rapid Eye Movement Sleep Behavior Disorder
- Goal
- Predict Parkinson or dementia risk
- Phase
- NA
- Status
- RECRUITING
- Sponsor
- Insel Gruppe AG, University Hospital Bern
- Study Type
- INTERVENTIONAL
- Enrollment
- 20 participants
- Conditions
- Parkinson Disease, REM Sleep Behavior Disorder, Dementia, Lewy Body
- Interventions
- PET/CT with 18-FDG, SPECT : 123 I-FP-CIT (DATSCAN), MRI
Plain-Language Summary
Goal: to spot which people with idiopathic REM sleep behavior disorder are most likely to develop Parkinson's disease or Lewy body dementia by finding early brain imaging signatures. Approach: participants have FDG-PET to map regional brain glucose metabolism, DAT SPECT with 123I‑FP‑CIT to measure dopamine transporter binding in the nigrostriatal pathway, and MRI for structural detail, then artificial intelligence analyzes those molecular and structural patterns to predict risk; these are diagnostic scans that do not involve drugs or change levodopa treatment. Eligibility: adults 18 and older with a confirmed iRBD diagnosis by movement disorder specialists, no known Parkinson’s or other neurodegenerative disorder, no clear parkinsonism on exam, and no other causes of RBD such as narcolepsy, moderate to severe sleep apnea, or abnormal neurological or MRI findings.
Locations
- Inselspital, University Clinic for Nuclear Medicine, Bern, Switzerland
Frequently Asked Questions
- What is this trial testing?
- This trial is studying PET/CT with 18-FDG. Goal: to spot which people with idiopathic REM sleep behavior disorder are most likely to develop Parkinson's disease or Lewy body dementia by finding early brain imaging signatures. Approach: participants have FDG-PET to map regional brain glucose metabolism, DAT SPECT with 123I‑FP‑CIT to measure dopamine transporter binding in the nigrostriatal pathway, and MRI for structural detail, then artificial intelligence analyzes those molecular and structural patterns to predict risk; these are diagnostic scans that do not involve drugs or change levodopa treatment. Eligibility: adults 18 and older with a confirmed iRBD diagnosis by movement disorder specialists, no known Parkinson’s or other neurodegenerative disorder, no clear parkinsonism on exam, and no other causes of RBD such as narcolepsy, moderate to severe sleep apnea, or abnormal neurological or MRI findings.
- Who can participate?
- Participants must be at least 18 Years.
- Where is this trial located?
- This trial is recruiting at 1 location.
- Does it cost anything to join?
- No. There is no cost to participate. Study-related care and treatment are provided at no charge.
- How long does the trial last?
- This trial is estimated to last approximately 1 year and 10 months.